Posts

Showing posts with the label Indolent non-Hodgkin lymphoma (NHL) competitive landscape

Indolent Non-Hodgkin Lymphoma (NHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Indolent Non-Hodgkin Lymphoma (NHL) is a slow-growing type of NHL, and the common subtypes of indolent NHL include follicular lymphoma (FL) and marginal zone lymphoma. Advanced-stage indolent or follicular non-Hodgkin lymphoma (NHL) is considered incurable by conventional therapy. However, only localized stage I or II follicular lymphoma may occasionally be cured with radiotherapy of involved sites. Indolent NHL usually responds well to treatment and can often be controlled for many years. Some people with indolent NHL never require treatment. Indolent NHL tends to come back (recur) after treatment. It can also become resistant to treatment over time. Some indolent NHLs can also change into a more aggressive type of NHL and will be treated as that type of NHL. Some indolent NHLs grow slowly and may spread to different body parts. ·        Indolent Non-Hodgkin Lymphoma (NHL) represents 40% of all NHL diagnosed cases; the overall five-year survival ra...

Indolent Non-Hodgkin Lymphoma (NHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Indolent Non-Hodgkin Lymphoma (NHL) is a slow-growing type of NHL, and the common subtypes of indolent NHL include follicular lymphoma (FL) and marginal zone lymphoma. Advanced-stage indolent or follicular non-Hodgkin lymphoma (NHL) is considered incurable by conventional therapy. However, only localized stage I or II follicular lymphoma may occasionally be cured with radiotherapy of involved sites. Indolent NHL usually responds well to treatment and can often be controlled for many years. Some people with indolent NHL never require treatment. Indolent NHL tends to come back (recur) after treatment. It can also become resistant to treatment over time. Some indolent NHLs can also change into a more aggressive type of NHL and will be treated as that type of NHL. Some indolent NHLs grow slowly and may spread to different body parts. ·        Indolent Non-Hodgkin Lymphoma (NHL) represents 40% of all NHL diagnosed cases; the overall five-year survival ra...

Indolent non-Hodgkin lymphoma (NHL) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
  Indolent NHL is a slow-growing type of NHL, and the common subtypes of indolent NHL include follicular lymphoma (FL) and marginal zone lymphoma. Conventional therapy considers advanced-stage indolent or follicular non-Hodgkin lymphoma (NHL) incurable. However, only localized stage I or II follicular lymphoma may occasionally be cured with radiotherapy of involved sites. Indolent NHL usually responds well to treatment and can often be controlled for many years. Some people with indolent NHL never require treatment. Indolent NHL tends to come back (recur) after treatment. It can also become resistant to treatment over time. Some indolent NHLs can also change into a more aggressive type of NHL and be treated as that type of NHL. Some indolent NHLs grow slowly and may spread to different body parts.   Indolent NHL represents 40% of all NHL diagnosed cases; NHL’s overall five-year survival rate is 71% on average and can be as high as 95% for certain types of indolent and loca...